Cargando…
Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome
BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is an important cause of acute kidney injury in children. It is primarily caused by dysregulation of the complement alternative pathway due to genetic mutations, mainly in complement factor H genes, or due to anti-factor H autoantibodies (anti-FH...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616678/ https://www.ncbi.nlm.nih.gov/pubmed/34840826 http://dx.doi.org/10.1155/2021/6904858 |
_version_ | 1784604396362924032 |
---|---|
author | Shawky, Shereen Safouh, Hesham Gamal, Mona Abbas, Mohammed M. Aboul-Enein, Azza Sawai, Toshihiro Fahmy, Yosra Selim, Heba |
author_facet | Shawky, Shereen Safouh, Hesham Gamal, Mona Abbas, Mohammed M. Aboul-Enein, Azza Sawai, Toshihiro Fahmy, Yosra Selim, Heba |
author_sort | Shawky, Shereen |
collection | PubMed |
description | BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is an important cause of acute kidney injury in children. It is primarily caused by dysregulation of the complement alternative pathway due to genetic mutations, mainly in complement factor H genes, or due to anti-factor H autoantibodies (anti-FH), leading to uncontrolled overactivation of the complement system. Early diagnosis and treatment of autoimmune HUS (AI-HUS) is essential and leads to a favorable outcome. METHODS: Fifty pediatric HUS patients and 50 age- and sex-matched controls were included in the study. Patients were subjected to full history taking, clinical examination, and laboratory testing. All candidates were subjected to an assessment of anti-FH in serum by a homemade enzyme-linked immunosorbent assay technique. RESULTS: A high frequency of serum anti-FH was detected in our aHUS patients. The disease onset of AI-HUS was mainly observed in March and April, with significantly higher rates in school-aged males. All patients who started immunosuppressives early together with plasmapheresis upon detection of their anti-FH had complete renal function recovery. CONCLUSION: The high frequency of AI-HUS revealed in Egyptian HUS children in our study highlights the importance of implementing anti-FH testing in Egypt to provide early recognition for immediate proper management, including early immunosuppressive therapy, and hence improving patient outcomes. |
format | Online Article Text |
id | pubmed-8616678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-86166782021-11-26 Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome Shawky, Shereen Safouh, Hesham Gamal, Mona Abbas, Mohammed M. Aboul-Enein, Azza Sawai, Toshihiro Fahmy, Yosra Selim, Heba Int J Nephrol Research Article BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is an important cause of acute kidney injury in children. It is primarily caused by dysregulation of the complement alternative pathway due to genetic mutations, mainly in complement factor H genes, or due to anti-factor H autoantibodies (anti-FH), leading to uncontrolled overactivation of the complement system. Early diagnosis and treatment of autoimmune HUS (AI-HUS) is essential and leads to a favorable outcome. METHODS: Fifty pediatric HUS patients and 50 age- and sex-matched controls were included in the study. Patients were subjected to full history taking, clinical examination, and laboratory testing. All candidates were subjected to an assessment of anti-FH in serum by a homemade enzyme-linked immunosorbent assay technique. RESULTS: A high frequency of serum anti-FH was detected in our aHUS patients. The disease onset of AI-HUS was mainly observed in March and April, with significantly higher rates in school-aged males. All patients who started immunosuppressives early together with plasmapheresis upon detection of their anti-FH had complete renal function recovery. CONCLUSION: The high frequency of AI-HUS revealed in Egyptian HUS children in our study highlights the importance of implementing anti-FH testing in Egypt to provide early recognition for immediate proper management, including early immunosuppressive therapy, and hence improving patient outcomes. Hindawi 2021-11-18 /pmc/articles/PMC8616678/ /pubmed/34840826 http://dx.doi.org/10.1155/2021/6904858 Text en Copyright © 2021 Shereen Shawky et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Shawky, Shereen Safouh, Hesham Gamal, Mona Abbas, Mohammed M. Aboul-Enein, Azza Sawai, Toshihiro Fahmy, Yosra Selim, Heba Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome |
title | Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome |
title_full | Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome |
title_fullStr | Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome |
title_full_unstemmed | Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome |
title_short | Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome |
title_sort | anti-factor h antibodies in egyptian children with hemolytic uremic syndrome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616678/ https://www.ncbi.nlm.nih.gov/pubmed/34840826 http://dx.doi.org/10.1155/2021/6904858 |
work_keys_str_mv | AT shawkyshereen antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome AT safouhhesham antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome AT gamalmona antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome AT abbasmohammedm antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome AT abouleneinazza antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome AT sawaitoshihiro antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome AT fahmyyosra antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome AT selimheba antifactorhantibodiesinegyptianchildrenwithhemolyticuremicsyndrome |